Ultrasound Detects 96% of Ovarian Cancers in Postmenopausal Women
A new study published in The Lancet Oncology highlights the effectiveness of the IOTA ADNEX ultrasound model in diagnosing ovarian cancer in postmenopausal women. This ultrasound-based diagnostic test showed a remarkable 96% accuracy in detecting ovarian cancer, outperforming the current standard of care in the UK, the Risk of Malignancy Index (RMI1), which identifies 83% of cases.
The research, led by Professor Sudha Sundar from the University of Birmingham, is the first head-to-head comparison of six diagnostic methods for ovarian cancer in postmenopausal women. Conducted with symptomatic patients who are at the highest risk, the study revealed that the IOTA ADNEX model is the most accurate diagnostic tool available. The test evaluates ultrasound features of ovarian lumps and achieves its high sensitivity when performed by sonographers who are specifically trained, certified, and undergo quality assurance.
Advancing Early Ovarian Cancer Detection
Although the model’s heightened sensitivity might lead to some false positives, consultations with patients, NHS experts, and cancer charities concluded that early detection of ovarian cancer outweighs the risks. Early and accurate diagnosis facilitates timely treatment and improves outcomes, making this tool particularly beneficial for high-risk populations.
Annwen Jones OBE, Chief Executive of Target Ovarian Cancer, emphasized the importance of early diagnosis and called for increased awareness of ovarian cancer symptoms. The researchers have also developed free online resources to train NHS staff in using the IOTA ADNEX model, ensuring accessibility and proper implementation.
The findings advocate for replacing the RMI1 test with the IOTA ADNEX ultrasound model in the UK, promising significant advancements in the early detection and management of ovarian cancer.
